Industry News
The Nicotine Pouch Aisle Gets Crowded: Celebrity-Backed Challengers Line Up Against ZYN
ZYN is having a landmark year — but it's no longer the only serious name in the nicotine pouch aisle. A wave of well-funded, celebrity-backed startups is pushing into the fast-growing category, and the nicotine pouch race is starting to reshape what shoppers see on the shelf.
A challenger built by ZYN's own inventor
The most talked-about newcomer is Sesh, a tobacco-free pouch brand positioning itself squarely against the market leader. Fortune reported that Sesh raised $40 million in venture funding led by 8VC — the firm co-founded by Palantir's Joe Lonsdale — with celebrity backers including Post Malone, Diplo, and comedian Andrew Schulz.
Its pitch has a twist: Sesh's formula was developed by Thomas Ericsson, the same chemist credited with inventing ZYN. The company says its recipe uses MCT oil to cut the gum irritation some users report with traditional nicotine-salt pouches.
CEO Max Cunningham has openly called ZYN the category's "800-pound gorilla," while arguing that Sesh's independence from Big Tobacco is a selling point.
The brand says it's already in more than 5,000 stores across the U.S. and Canada and is on pace for roughly 500 percent year-over-year growth. The celebrity money keeps coming. The New York Post reported on July 1, 2026, that more high-profile names — including DJ Khaled — are lining up behind pouch startups chasing ZYN's lead, a sign of how much investor attention the category is drawing.
Why the timing matters
The challengers are arriving just as the incumbent scored a major regulatory milestone. On June 30, 2026, the FDA issued modified-risk orders for 20 ZYN products made by Philip Morris International's Swedish Match unit — the first time a nicotine pouch has been cleared to make a reduced-risk claim versus cigarettes.
That decision validated the whole category and, in the eyes of investors, made it worth fighting over. A crowded field tends to mean more flavors, more nicotine-strength options, and sharper pricing as brands compete for placement. It can also mean confusion, so it's worth separating hype from substance.
The caveats shoppers should keep in mind
None of this changes what these products are. Nicotine pouches are addictive, and "lower risk than cigarettes" is not the same as safe. The FDA's clearance for ZYN applies to specific products and comes with strict conditions; it is not a blanket endorsement of the category, and it does not extend to challenger brands that haven't been through the same review.
Health officials and youth-prevention advocates continue to warn about appeal to young people, and pouches are for adults only. Shoppers looking for alternative oral products may also be interested in premium tobacco wraps or filtered cigars, though these contain combustible tobacco unlike pouches.
What it means for shoppers
- More choice is coming: Expect a wider mix of pouch brands, strengths, and flavors as challengers fight for shelf space.
- Incumbents still lead on standing: Only ZYN currently carries the FDA's reduced-risk marketing clearance; newer brands are competing on formula and price, not regulatory status.
- Rules and taxes vary: Several states added or raised taxes on oral nicotine in 2026, and state tobacco laws differ by location — so selection and price depend on where you are.
The bottom line
The nicotine pouch category has gone from a one-name game to a genuine contest, with ZYN's FDA milestone drawing a crowd of ambitious, celebrity-funded rivals. That's good for choice — but the underlying product is still addictive, still adults-only, and still not something to treat casually.
A2Z Tobacco sells tobacco products, nicotine pouches and related products intended for adults 21 and older. Valid age verification is required, and product availability, pricing, and taxes depend on applicable state and local law. Nicotine is addictive and carries health risks. This article is general information, not legal, tax, or medical advice.